

The following Listing of the claims will replace all prior versions and all prior listings of the claims in the present application.

Claims 1-38, 42, 44-73, 75, 76, 80-84 and 108 are cancelled.

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Canceled)

37. (Canceled)

38. (Canceled)

39. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell , wherein said stem cell is at least 30% pure.

40. (Previously Amended) The isolated stem cell of any one of claims 39 and 85 through 94, wherein said nestin-positive human pancreatic or liver stem cell is also GLP-1R-positive.

41. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 30% pure.

42. (Canceled)

43. (Previously Amended) The isolated stem cell of any one of 109, 110 and 111, wherein said stem cell differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

44. (Canceled)

45. (Canceled)

46. (Canceled)

47. (Canceled)

48. (Canceled)

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Canceled)

55. (Canceled)

56. (Canceled)

57. (Canceled)

58. (Canceled)

59. (Canceled)

60. (Canceled)

61. (Canceled)

62. (Canceled)

63. (Canceled)

64. (Canceled)

65. (Canceled)

66. (Canceled)

67. (Canceled)

68. (Canceled)

69. (Canceled)

70. (Canceled)

71. (Canceled)

72. (Canceled)

73. (Canceled)

74. (Previously Amended) A pharmaceutical composition comprising the isolated stem cell of claim 109, 110 or 111 admixed with a physiologically compatible carrier.

75. (Canceled)

76. (Canceled)

77. (Previously Presented) An isolated nestin-positive, GLP-1R-positive or nestin and GLP-1R-positive human pancreatic stem cell isolated by:

a) removing a pancreatic islet from a donor;

b) removing cells from said pancreatic islet wherein said islet comprises a plurality of cell types comprising stem cells; and

c) separating said stem cells from said plurality of cells.

78. (Previously Presented) The isolated stem cell of claim 77 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

79. (Previously Presented) A pharmaceutical composition comprising the isolated stem cell of claim 77 admixed with a physiologically compatible carrier.

80. (Canceled)

81. (Canceled)

82. (Canceled)

83. (Canceled)

84. (Canceled)

85. (Previously Amended) An isolated composition comprising at least 40%, nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 40% pure.

86. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 50% pure.

87. (Previously Amended) An isolated composition comprising at least 60%, nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 60% pure.

88. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 70% pure.

89. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 80% pure.

90. (Previously Amended) An isolated composition comprising at least 85%, nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 85% pure.

91. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 90% pure.

92. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 95% pure.

93. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 98% pure.

94. (Previously Amended) An isolated nestin-positive human pancreatic or liver stem cell

that is not a neural stem cell wherein said stem cell is at least 99% pure.

95. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 40% pure.

96. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 50% pure.

97. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 60% pure.

98. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 70% pure.

99. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 80% pure.

100. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 85% pure.

101. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 90% pure.

102. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 95% pure.

103. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 98% pure.

104. (Previously Amended) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said stem cell is at least 99% pure.

105. (Previously Presented) An isolated, nestin-positive, GLP-1R positive or nestin and GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said cell is isolated from a pancreatic islet.

106. (Previously Presented) The isolated stem cell of claim 105 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

107. (Previously Presented) A pharmaceutical composition comprising the stem cell of claim 105, admixed with a physiologically compatible carrier.

108. (Canceled)

109. (Previously Presented) An isolated nestin-positive human pancreatic or liver stem cell that is not a neural stem cell.

110. (Previously Presented) The isolated stem cell of claim 109, wherein said nestin-positive human pancreatic or liver stem cell is also GLP-1R-positive.

111. (Previously Presented) An isolated GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell.